Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Get Free Report) Director Bruce Polsky sold 8,750 shares of the stock in a transaction that occurred on Thursday, November 19th. The stock was sold at an average price of $4.03, for a total transaction of $35,262.50. Following the completion of the sale, the director owned 149,830 shares in the company, valued at $603,814.90. This represents a 5.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Bruce Polsky also recently made the following trade(s):
- On Wednesday, November 18th, Bruce Polsky sold 18,252 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $3.95, for a total transaction of $72,095.40.
- On Monday, November 16th, Bruce Polsky sold 14,254 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.27, for a total transaction of $60,864.58.
- On Tuesday, November 17th, Bruce Polsky sold 8,720 shares of Atea Pharmaceuticals stock. The shares were sold at an average price of $4.03, for a total transaction of $35,141.60.
Atea Pharmaceuticals Trading Down 1.5%
Shares of AVIR traded down $0.06 during mid-day trading on Thursday, reaching $3.93. 291,342 shares of the stock traded hands, compared to its average volume of 301,285. The company has a market cap of $315.58 million, a price-to-earnings ratio of -2.02 and a beta of 0.76. Atea Pharmaceuticals, Inc. has a 1 year low of $2.92 and a 1 year high of $6.45. The firm has a fifty day moving average price of $4.68 and a 200 day moving average price of $4.94.
Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.11. On average, sell-side analysts anticipate that Atea Pharmaceuticals, Inc. will post -1.60 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on AVIR shares. Wall Street Zen upgraded Atea Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a research report on Thursday, October 15th. Finally, Morgan Stanley upped their price objective on shares of Atea Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $8.00.
Read Our Latest Report on AVIR
Atea Pharmaceuticals News Summary
Investors following AVIR have been watching these news items:
- Positive Sentiment: Morgan Stanley increased its price target to $8 from $7. The firm kept an “equal weight” rating, so the higher target is a positive signal but not an endorsement to outperform. Article: Atea Pharmaceuticals Stock Price Expected to Rise, Morgan Stanley Analyst Says
- Negative Sentiment: Directors Bruce Polsky and Bruno Lucidi reported multiple stock sales over the week, totaling about 79,000 shares. Repeated insider selling may weigh on sentiment, although the disclosed transactions do not by themselves indicate why the directors sold. Article: Atea Pharmaceuticals Insider Buying and Selling
Institutional Trading of Atea Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in AVIR. Empowered Funds LLC bought a new stake in shares of Atea Pharmaceuticals during the 3rd quarter worth $475,000. Engineers Gate Manager LP purchased a new position in Atea Pharmaceuticals in the second quarter worth $78,000. Spark Investment Management LLC bought a new position in Atea Pharmaceuticals in the second quarter valued at $75,000. Headlands Technologies LLC bought a new position in Atea Pharmaceuticals in the second quarter valued at $77,000. Finally, Wellington Management Group LLP increased its stake in Atea Pharmaceuticals by 262.7% in the second quarter. Wellington Management Group LLP now owns 206,785 shares of the company’s stock valued at $962,000 after acquiring an additional 149,776 shares during the last quarter. Hedge funds and other institutional investors own 86.67% of the company’s stock.
About Atea Pharmaceuticals
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing oral antiviral medicines for serious viral diseases. Its research centers on compounds intended to interfere with viral replication. The company’s investigational portfolio has included bemnifosbuvir, an oral antiviral candidate studied for COVID-19, as well as programs targeting other viral infections, including dengue. These medicines are investigational and are not established marketed treatments.
Recommended Stories
- Five stocks we like better than Atea Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
